The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

SWOG study shows neoadjuvant Keytruda helps prevent recurrence in high-risk melanoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Patients with high-risk melanoma who received the immunotherapy drug Keytruda (pembrolizumab) both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

MD Anderson’s Boot Walk to End Cancer raises $1.4M

The University of Texas MD Anderson Cancer Center hosted its ninth annual Boot Walk to End Cancer fundraising event on Nov. 2, in the Texas Medical Center. This year, the Boot Walk’s 7,000+ in-person participants and 1,200+ virtual participants from Houston and around the world joined together to raise $1.4 million to support the institution’s mission to end cancer. 
In Brief

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account